文拉法辛在慢性阻塞性肺疾病伴焦虑抑郁治疗中的应用

Application of Venlafaxine in the treatment of chronic obstructive pulmonary disease with anxiety anddepression.

ES评分 0

DOI
刊名
Journal of International Psychiatry
年,卷(期) 2016, 43(2)
作者
作者单位

陕西省第四人民医院呼吸内科 ;
第四军医大学西京医院呼吸内科 ;
西安市长安医 院呼吸内科 ;

摘要
目的 探讨文拉法辛在慢性阻塞性肺疾病伴焦虑抑郁治疗中的临床应用前景。方法 将我院于2012年1月~2013年12月收住的86例慢性阻塞性肺疾病(COPD)合并焦虑抑郁患者随机分为对照组和试验组,每组各43例。对照组采取常规治疗,试验组在对照组常规基础上加用文拉法辛治疗。治疗4周后,对比两组患者的肺功能、生活质量、负性情绪及不良反应。结果 通过4周治疗,试验组患者FEV1占预计值和FEV1 /FVC显著高于对照组(P <0.01),SGRQ、HAMA、HAMD评分明显低于对照组(P <0.01),两组之间的不良反应发生率无统计学差异(P >0.05)。结论 文拉法辛能明显改善COPD患者的焦虑及抑郁症状,提高患者生活质量,可在临床推广应用。
Abstract
Objective To explore the clinical perspectives of Venlafaxine in the treatment of chronic obstructivepulmonary disease with anxiety and depression. Methods 86 cases of COPD complicated with anxiety and depressionpatients from January 2012 to December 2013 in our hospital,andtheywererandomlydividedintocontrol groupand ,andtheywererandomlydividedintocontrol groupand and they were randomly divided into control group andexperimental group. The control group received routine treatment,experimental groupreceivedvenlafaxineontheba- ,experimental groupreceivedvenlafaxineontheba- experimental group received venlafaxine on the ba-sis of routine treatment,after4weeks treatment,comparedthepulmonaryfunction,lifequality,negativeemotion ,after4weeks treatment,comparedthepulmonaryfunction,lifequality,negativeemotion after 4 weeks treatment,comparedthepulmonaryfunction,lifequality,negativeemotion ,comparedthepulmonaryfunction,lifequality,negativeemotion compared the pulmonary function,lifequality,negativeemotion ,lifequality,negativeemotion life quality,negativeemotion ,negativeemotion negative emotionand adverse effects of these two. Results After 4 weeks’ treatment,theFEV1andFEV1/FVCof experimental group ,theFEV1andFEV1/FVCof experimental group the FEV1 and FEV1 /FVC of experimental groupwere significantly higher than control group,SGRQ,HAMAandHAMDscoresweremarkedlylowerthancontrolgroup ,SGRQ,HAMAandHAMDscoresweremarkedlylowerthancontrolgroup SGRQ,HAMAandHAMDscoresweremarkedlylowerthancontrolgroup ,HAMAandHAMDscoresweremarkedlylowerthancontrolgroup HAMA and HAMD scores were markedly lower than control group(P <0.01),andnostatisticaldifferenceinadverseeffectratebetweenthesetwogroups( ),andnostatisticaldifferenceinadverseeffectratebetweenthesetwogroups( and no statistical difference in adverse effect rate between these two groups(P >0.05). ). Conclusion Ven-lafaxine could improve anxiety and depressive symptoms of patients with COPD,andimprovetheirlifequality,there- ,andimprovetheirlifequality,there- and improve their life quality,there- ,there- there-fore it was suitable for clinical promotion.
关键词
文拉法辛;慢性阻塞性肺疾病;焦虑;抑郁
KeyWord
Venlafaxine;Chronicobstructivepulmonarydisease;Anxiety;Depression.
基金项目
页码 291-293
  • 参考文献
  • 相关文献
  • 引用本文

廖建军*,戚好文,杨 娜,李 宁. 文拉法辛在慢性阻塞性肺疾病伴焦虑抑郁治疗中的应用 [J]. 国际精神病学杂志. 2016; 43; (2). 291 - 293.

  • 文献评论

相关学者

相关机构